Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach - Influenza - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2017-10-03 19:39:49		Visterra’s Monoclonal Antibody in Development for the Treatment of Influenza A, VIS410, Demonstrated Significant Antiviral Activity and Reduced Duration of Respiratory Symptoms in Phase 2a Challenge Study – Study Ach Add to Reading List Source URL: www.visterrainc.com Download Document from Source Website File Size: 127,86 KB Share Document on Facebook